Citations

Mayo Clinic

Showing 10 of 108551 citations.

Digital Determinants of Health: AI and the need for equity-focused innovation in digital health
Celi, Leo Anthony , Kashani, Kianoush

No container title available | March 15, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.52843/cassyni.rnbnh2 Get It

*Nature Reviews Nephrology* welcomes you to this webinar, in which our two speakers — Leo Celi and Kianoush Kashani — will present on the theme of Digital Determinants of Health, with a focus on artificial intelligence (AI) and the need for equity-focused innovation. The webinar will be held on 14th of March 2024 — World Kidney Day — which this year focuses on “Advancing equitable access to care and optimal medication practice”. In their [Comment](https://www.nature.com/articles/s41581-023-00763-4.epdf?sharing_token=ihZn7Tzp1ixBfK7a3X_6x9RgN0jAjWel9jnR3ZoTv0NaWQBzIFRPdPKT7AS3IVVHez49nwrLVjZJyLsCUt5034qu70IjW6yS7U3gUuTEQjm0O_u1j1PiMZLzRs7qKAyY_28RvtE3kXcXmwKeyufyUyKP715Wx73c6p6Bfp6w6Sg%3D) “Digital determinants of health: opportunities and risks amidst health inequities”, Leo Celi and colleagues argue that given the current digital revolution, digital tools and AI applications in health care must be developed with equity at the forefront to avoid perpetuating historical biases and inequities. With their [Consensus Statement](https://www.nature.com/articles/s41581-023-00744-7) on “Digital health and acute kidney injury”, Kianoush Kashani and colleagues highlight some of the potential applications of digital health tools in nephrology, as well as the need for equitable digitization. Artificial Intelligence: The digital determinant of health to rule them all Artificial intelligence (AI) is poised to be the biggest digital determinant of health. From healthcare, to education, to law enforcement, AI can theoretically augment every human task that involves thinking. We will see every decision-making infiltrated by AI. This is why AI is different. Most technologies are much narrower in scope, and therefore, easier to regulate. In addition, the data that we use to build AI reflects everything about the systems we would like to disrupt, both good and bad. Behind the façade of AI lies our legacy systems with all their flaws. The biggest threat to AI delivering its promise stems from the risk of cementing the structural inequities that permeate every aspect of society. AI provides an opportunity to inch us closer to a better care delivery system, but it will require us to design an equity-focused sociotechnical ecosystem. Engineering AI in a vacuum that does not build capacity nor include cultural transformation of how we learn and how we work together will be a waste of time and money, and a huge opportunity cost. To avert the disaster from AI, we need to diversify those sitting at the table. We need to diversify those who are developing and deploying AI. Digital health in acute kidney injury management Acute kidney injury (AKI) is a highly prevalent clinical syndrome that substantially impacts patient outcomes. It is accepted by the clinical communities that the management of AKI is time sensitive. Unfortunately, despite growing proof of its preventability, AKI management remains suboptimal in community, acute care, and post-acute care settings. Digital health solutions comprise various tools and models to improve care processes and patient outcomes in multiple medical fields. AKI development, progression, recovery, or lack thereof, offers tremendous opportunities for developing, validating, and implementing digital health solutions in multiple settings.
Ovarian Tissue Cryopreservation versus Other Fertility Techniques for Chemoradiation-Induced Premature Ovarian Insufficiency in Women: A Systematic Review and Future Directions
Chaudhri, Eman N. , Salman, Ayman, Awartani, Khalid, Khan, Zaraq , Hashmi, Shahrukh K.

Life | March 15, 2024 | Volume: 14 | Issue: 3 | Pages: 393

10.3390/life14030393 | PMID 38541717 Get It

Current advances in cancer therapy have increased survival, emphasizing the need for life quality improvement. Fertility loss is common post-chemotherapy. Current guidelines establish embryo and oocyte cryopreservation to address premature ovarian insufficiency (POI). Ovarian tissue cryopreservation has also recently become an acceptable option for fertility preservation, particularly as it is the only option for pre-pubertal patients. Few definitions for optimum fertility outcomes, and few systematic reviews comparing embryo, oocyte, and ovarian tissue cryopreservation as a means of fertility preservation (FP) in pre- and post-pubertal female cancer patients exist. This systematic review aims to improve understanding of gonadotoxic effects of chemoradiation therapy in cancer patients, to analyze the different fertility preservation techniques and procedures available to women with chemoradiation induced ovarian insufficiency, and to compare and recognize the benefits of each technique in restoring fertility, sexual hormone function, and quality of life. Searches were conducted electronically on PubMed, Cochrane, and EBSCOHost, including clinical trials, prospective, and retrospective studies of female cancer patients undergoing anti-cancer therapy, with predefined MeSH terminology. Data were collected, analyzed, and compared. Non-randomized clinical studies were evaluated for risk bias through the Newcastle–Ottawa Scale. In total, 23 studies were included. From there, 647 patients opted for oocyte cryopreservation, 267 for embryo cryopreservation, and 1382 for ovarian tissue cryopreservation (OTC). A total of 175, 18, and 121 live births resulted respectively from oocyte, embryo, and OTC, respectively. Studies without live births discussed other fertility markers as indicators of improvement in sexual hormone function and fertility. The gonadotoxic effects of chemotherapy call for FP intervention. Oocyte and embryo cryopreservation/implantation are well-established procedures. With changing trends and life quality consideration, OTC is a promising interventional method for pre-pubertal patients facing the prospect of fertility loss.
Motility Disorders of the Stomach: Pathophysiologic Mechanisms and Evaluation
Cangemi, David J. , Lacy, Brian E. , Cangemi, David

Foregut: The Journal of the American Foregut Society | March 15, 2024 | Volume: 4 | Issue: 2 | Pages: 182-190

10.1177/26345161241239607 Get It

Gastroparesis (GP) is a disorder characterized by symptoms of nausea, vomiting, early satiety, abdominal pain, and/or bloating in the setting of delayed gastric emptying and the absence of a mechanical obstruction. Though the epidemiology and many pathophysiologic mechanisms have been well-established, GP remains an incompletely understood gastrointestinal disorder, and recent data has challenged existing concepts regarding the etiology, diagnosis, and treatment of GP. Thus, our understanding of GP is evolving and with this comes the promise of novel diagnostic methods and treatments, both of which are sorely needed for this historically vexing disorder, which presents unique challenges to patients and providers alike. In this section, we will review existing principles pertaining to the pathophysiology and evaluation of GP, and contrast this with recent data, some of which challenges the historical perspective. In so doing, we aim to provide the reader with an updated and sophisticated view on the approach to GP moving forward.
A case report of vaping-associated sudden cardiac arrest in a young healthy patient
Ahmed, Hasaan , Palicherla, Anirudh , May, Joshua, Thirumalareddy, Joseph , Ismayl, Mahmoud , Goldsweig, Andrew M.

Annals of Medicine & Surgery | March 15, 2024 | Volume: 86 | Issue: 5 | Pages: 3042-3046

10.1097/ms9.0000000000001907 | PMID 38694286 Get It

Introduction and importance: While vaping has increased significantly among young individuals, the effects of vape aerosol constituents on cardiac electrophysiological dynamics remain unknown. Case presentation: A 22-year-old female with a history of energy vaping presented with cardiac arrest. Found to have no pulse, CPR was started and an initial rhythm of ventricular tachycardia was obtained. Shock was administered with a follow-up rhythm of ventricular fibrillation. She was emergently defibrillated and entered atrial fibrillation with rapid ventricular response. Toxicology and troponins were all negative. Left heart catheterization and cardiac MRI were unremarkable. She was discharged with an external defibrillation vest and a tentative plan for outpatient electrophysiology study in the setting of negative work-up for cardiopulmonary arrest. Clinical discussion: Vaping-induced sudden cardiac arrest may be attributed to a reduction in cardiac repolarization reserve. Exposure to vegetable glycerin and propylene glycol, substances present in nearly all vape products, have been found to incite arrhythmias and disrupt cardiac conduction in animals. Acrolein, an aldehyde byproduct of glycerin, has also been found to induce arrhythmias due to autonomic dysfunction. Increased intracellular calcium concentration and free radical damage, which occur as a result of inhaling particulate matter generated from e-cigarettes, further propagates the risk of arrhythmia. Conclusion: The effects of inhaling vape aerosols remain not fully understood. While there is a perceived notion that nicotine-free aerosols may be harmless, that remains unclear. Further studies are needed to evaluate proarrhythmogenic effects and autonomic dysfunction from the various chemical substances present in vape aerosols.
Pharmacotherapeutic Considerations in the Treatment of Nontuberculous Mycobacterial Infections: A Primer for Clinicians
Cimino, Christo , Rivera, Christina G. , Pearson, Jeffrey C , Colton, Benjamin , Slain, Douglas , Mahoney, Monica V. , Rivera, Christina G , Mahoney, Monica V

Open Forum Infectious Diseases | March 15, 2024 | Volume: 11 | Issue: 4 | Pages: No page available

10.1093/ofid/ofae128 | PMID 38560605 Get It

Abstract Nontuberculous mycobacteria (NTM) can cause a variety of infections, including serious pulmonary disease. Treatment encompasses polypharmacy, with a targeted regimen of 2–5 active medications, depending on site of infection, species, and clinical characteristics. Medications may include oral, intravenous, and inhalational routes. Medication acquisition can be challenging for numerous reasons, including investigational status, limited distribution models, and insurance prior authorization. Additionally, monitoring and managing adverse reactions and drug interactions is a unique skill set. While NTM is primarily medically managed, clinicians may not be familiar with the intricacies of medication selection, procurement, and monitoring. This review offers insights into the pharmacotherapeutic considerations of this highly complex disease state, including regimen design, medication acquisition, safety monitoring, relevant drug–drug interactions, and adverse drug reactions.
Navigating the Landscape of Translational Geroscience in Canada: A Comprehensive Evaluation of Current Progress and Future Directions
Hajj‐Boutros, Guy , Faust, Andréa, Kim, Perry, Chevalier, Stéphanie , Bergman, Howard , Burford, Jessica S , Carrington‐Lawrence, Stacy, Côté, Hélène, Fowler, Robert , Gouspillou, Gilles , Harrington, Lea , Imani, Mahdi , Kirkland, James L. , Mallette, Frédérick A. , Newman, John C. , Pullman, Daryl , Sierra, Felipe , Rylett, R. Jane , Duque, Gustavo , Chevalier, Stéphanie , Farrelly, Colin , Lautrup, Sofie , Howlett, Susan , Kirkland, James, Morais, José A , Newman, John C , Van Raamsdonk, Jeremy , Watt, Jennifer , Duque, Gustavo , Muscedere, John , Abumrad, Naji N. , Aubertin‐Leheudre, Mylène , Bowdish, Dawn M. E. , Dawe, David E. , Barreto, Philipe de Souto , Howlett, Susan E. , Kuchel, George A. , Morais, José A.

The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences | March 15, 2024 | Volume: 79 | Issue: 7 | Pages: No page available

10.1093/gerona/glae069 | PMID 38486371 Get It

Abstract The inaugural Canadian Conferences on Translational Geroscience were held as 2 complementary sessions in October and November 2023. The conferences explored the profound interplay between the biology of aging, social determinants of health, the potential societal impact of geroscience, and the maintenance of health in aging individuals. Although topics such as cellular senescence, molecular and genetic determinants of aging, and prevention of chronic disease were addressed, the conferences went on to emphasize practical applications for enhancing older people’s quality of life. This article summarizes the proceeding and underscores the synergy between clinical and fundamental studies. Future directions highlight national and global collaborations and the crucial integration of early-career investigators. This work charts a course for a national framework for continued innovation and advancement in translational geroscience in Canada.
Use of hydroxocobalamin to treat intraoperative vasoplegic syndrome refractory to vasopressors and methylene blue during liver transplantation
Pai, Sher‐Lu , Torp, Klaus D. , Insignares, Vianca C., DeMaria, Samuel , Giordano, Chris , Logvinov, Ilana I. , Chadha, Ryan , Aniskevich, Stephen , Li, Zhuo , Chadha, Ryan , Aniskevich, Stephen , Pai, Sher-Lu , Logvinov, Ilana , Li, Zhuo

Clinical Transplantation | March 15, 2024 | Volume: 38 | Issue: 3 | Pages: No page available

10.1111/ctr.15271 | PMID 38485687 Get It

AbstractIntroductionFor patients with catecholamine‐resistant vasoplegic syndrome (VS) during liver transplantation (LT), treatment with methylene blue (MB) and/or hydroxocobalamin (B12) has been an acceptable therapy. However, data on the effectiveness of B12 is limited to case reports and case series.MethodsWe retrospectively reviewed records of patients undergoing LT from January 2016 through March 2022. We identified patients with VS treated with vasopressors and MB, and abstracted hemodynamic parameters, vasopressor requirements, and B12 administration from the records. The primary aim was to describe the treatment efficacy of B12 for VS refractory to vasopressors and MB, measured as no vasopressor requirement at the conclusion of the surgery.ResultsOne hundred one patients received intraoperative VS treatment. For the 35 (34.7%) patients with successful VS treatment, 14 received MB only and 21 received both MB and B12. Of the 21 patients with VS resolution after receiving both MB and B12, 17 (89.5%) showed immediate, but transient, hemodynamic improvements at the time of MB administration and later showed sustained response to B12.ConclusionImmediate but transient hemodynamic response to MB in VS patients during LT supports the diagnosis of VS and should prompt B12 administration for sustained treatment response.
P18 Proteomic analysis of cutaneous lupus erythematosus (CLE) dermal infiltrates and control skin reveals differentially upregulated and downregulated pathways
Meves, Alexander , Dasari, Surendra , Popovic-Silwerfeldt, Karin, Charlesworth, M. Cristine , Oke, Vilija , Niewold, Timothy B. , Lehman, Julia S. , Madden, Benjamin , Svenungsson, E

Poster Presentations | March 15, 2024 | Volume: No volume available | Issue: No issue available | Pages: A55-A56

10.1136/lupus-2024-el.72 Get It

O40 Impact of glucocorticoid dose on complete response, serious infections, and mortality during the initial therapy of lupus nephritis: a systematic review and meta-analysis of the standard of care arms of randomized controlled trials
Sánchez-Rodríguez, Alain , Flores‐Gouyonnet, Jaime , Dall’Era, Maria , Houssiau, Frédéric , Tamirou, Farah, Crowson, Cynthia S. , Putman, Michael , Figueroa‐Parra, Gabriel , Cuéllar‐Gutiérrez, María C. , González‐Treviño, Mariana , Meade‐Aguilar, José A. , Prokop, Larry J. , Murad, M. Hassan , Rovin, Brad H. , Fervenza, Fernando C. , Duarte‐García, Alí

Oral Presentations | March 15, 2024 | Volume: No volume available | Issue: No issue available | Pages: A37-A38

10.1136/lupus-2024-el.49 Get It